×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.
20141835 2010
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
GeneticVariation
CLINVAR
Improved survival with MEK inhibition in BRAF-mutated melanoma.
22663011 2012
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.
19238210 2009
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
22351686 2012
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
22389471 2012
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Genetic predictors of MEK dependence in non-small cell lung cancer.
19010912 2008
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
22972589 2013
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.
23833300 2013
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder.
19404918 2009
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors.
25656898 2015
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
GeneticVariation
CLINVAR
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
23248257 2013
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.
25370471 2015
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
GeneticVariation
CLINVAR
Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.
21639808 2011
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
GeneticVariation
CLINVAR
These results suggest that BRAF mutation in melanoma is most likely to occur prior to the development of metastatic disease.
16096377 2005
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Determinants of BRAF mutations in primary melanomas.
14679157 2003
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.
23715574 2013
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
24508103 2014
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
23918947 2013
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
GeneticVariation
CLINVAR
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
24508103 2014
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma.
23031422 2012
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
GeneticVariation
CLINVAR
Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers.
12068308 2002
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
GeneticVariation
CLINVAR
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
23918947 2013
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
GeneticVariation
CLINVAR
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
22048237 2012
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
22735384 2012
×
Entrez Id: 673
Gene Symbol: BRAF
BRAF
melanoma
1.000
CausalMutation
CLINVAR
Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations.
23317446 2013